Company
AbbVie
AbbVie has 61 drugs tracked on RxWires: 4 post-market, 8 approved, 10 in Phase 3, 1 in Phase 2/3, 15 in Phase 2, 3 in Phase 1/2, 20 in Phase 1.
- Ticker
- ABBV
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| BOTOX | Post-Market | Upper Facial Lines |
| Levodopa-carbidopa intestinal gel (LCIG) | Post-Market | Advanced Idiopathic Parkinson's Disease |
| Pancrelipase | Post-Market | Exocrine Pancreatic Insufficiency (EPI) |
| Cepheid POC HCV Viremia (RNA) test | Post-Market | Hepatitis C |
| NIMBEX PRESERVATIVE FREE | Approved | |
| LUPANETA PACK | Approved | |
| TRIDIONE | Approved | |
| DUOPA | Approved | |
| NORVIR | Approved | |
| HUMIRA | Approved | |
| VIIBRYD | Approved | |
| ACULAR LS | Approved | |
| Cariprazine | Phase 3 | Autism Spectrum Disorder |
| Surabgene Lomparvovec (ABBV-RGX-314) | Phase 3 | Neovascular Age-related Macular Degeneration |
| Ubrogepant | Phase 3 | Migraine |
| Venetoclax | Phase 3 | Chronic Lymphocytic Leukemia (CLL) |
| Upadacitinib | Phase 3 | Non-Segmental Vitiligo |
| Atogepant | Phase 3 | Episodic Migraine |
| ABT-874 | Phase 3 | Moderate to Severe Plaque Psoriasis |
| Elagolix | Phase 3 | Uterine Fibroids |
| AGN-151586 | Phase 3 | Glabellar Lines |
| risankizumab | Phase 3 | Psoriasis |
| Glecaprevir/Pibrentasvir Adult Formulation | Phase 2/3 | Hepatitis C Virus (HCV) |
| ABT-122 | Phase 2 | Rheumatoid Arthritis |
| Lutikizumab | Phase 2 | Psoriatic Arthritis |
| TrenibotulinumtoxinE and OnabotulinumtoxinA | Phase 2 | Upper Facial Lines |
| Budigalimab | Phase 2 | Human Immuno-deficiency Virus (HIV) Disease |
| Aflibercept | Phase 2 | Diabetic Retinopathy, DR |
| BOTOX Dose A | Phase 2 | Ventral Hernia |
| Dexamethasone | Phase 2 | Multiple Myeloma |
| Emraclidine 30 mg | Phase 2 | Schizophrenia |
| ABT-450/ritonavir (r) | Phase 2 | Chronic Hepatitis C |
| ABT-288 | Phase 2 | Alzheimer's Disease |
| ABBV-8E12 | Phase 2 | Progressive Supranuclear Palsy |
| ABT-450/r | Phase 2 | Hepatitis C, Chronic |
| Volociximab | Phase 2 | Pancreatic Cancer |
| ABBV-722 | Phase 2 | Rheumatoid Arthritis |
| Livmoniplimab | Phase 2 | Urothelial Carcinoma |
| Biospecimen Collection | Phase 1/2 | Recurrent Diffuse Large B-Cell Lymphoma |
| Ibrutinib | Phase 1/2 | Refractory Follicular Lymphoma |
| azacitadine | Phase 1/2 | Non-Hodgkin Lymphoma (NHL) |
| ABBV-932 | Phase 1 | Healthy Volunteer |
| Fosigotifator | Phase 1 | Major Depressive Disorder (MDD) |
| ABBV-706 | Phase 1 | Advanced Solid Tumors |
| SC-007 | Phase 1 | Colorectal Cancer (CRC) |
| ABBV-295 | Phase 1 | |
| Nacresertib | Phase 1 | |
| ABBV-101 | Phase 1 | Hematologic Cancer |
| ABBV-8736 | Phase 1 | Healthy Volunteer |
| ABT-199 | Phase 1 | Non-Hodgkin's Lymphoma |
| veliparib | Phase 1 | Locally Advanced Rectal Cancer |
| chemotherapy | Phase 1 | Malignancies |
| ABBV-155 | Phase 1 | Advanced Solid Tumors |
| ABBV-903 | Phase 1 | Healthy Volunteer |
| ABBV-927 | Phase 1 | Pancreatic Cancer |
| ABBV-467 | Phase 1 | Multiple Myeloma (MM) |
| ABBV-253 | Phase 1 | Advanced Solid Tumors |
| ABT-767 | Phase 1 | Fallopian Tube |
| ABBV-711 | Phase 1 | Advanced Squamous Tumors |
| ABT-308 | Phase 1 | Asthma |
| Etentamig (ABBV-383) | Phase 1 | Multiple Myeloma |
Latest
- Label updated: CARBIDOPA AND LEVODOPA
- Label updated: VILAZODONE HYDROCHLORIDE
- abbvie filed 8-K
- abbvie filed 8-K
- Label updated: ADALIMUMAB
Follow AbbVie on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.